The research pipeline is full of junk. More monoclonal antibodies with limited efficacy....specialized chemotherapy on the newest receptor pathway (JAK)...and more rehashes and drug combos. We're only getting 1 new abx a year....pitiful. Oh look, another insulin analog. Great stuff! And then we have this Alzheimer's marker that doesn't haven great diagnostic accuracy. Such a shame.